[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"deep-vein-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:deep-vein-thrombosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,53,84,104,130,157,187,207,226,253,275,305,327,356,379,405,428,453,480,506,541,571,600,626],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111",false,"NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria","ALL","18 Years",{"count":20,"type":21},1424,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[27,28,29,30,31,32],"Venous Thromboembolism","Deep Vein Thrombosis","Pulmonary Embolism","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[34,35,36,37,38,39],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","RECRUITING","2026-06-22",{"date":43,"type":44},"2026-06-25","ACTUAL",{"date":46,"type":44},"2024-07-19",{"date":48,"type":21},"2028-11-19",{"name":50,"class":51},"University Hospital, Angers","OTHER_GOV",37,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100641028","profunda-femoris-vein-thrombosis-evaluation-and-clearance-to-improve-outcomes-of-endovascular-treatment-for-acute-iliofemoral-deep-vein-thrombosis-100641028","NCT07622199","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 85 years;\n2. Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and PFV (confirmed by preoperative ultrasound, CT venography, or intraoperative venography);\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patient receives endovascular treatment with PMT;\n5. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb within the past 2 years;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents;\n4. Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension;\n5. Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications;\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders;\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or thrombocytopenia (platelet count \\\u003C 80,000\u002FmL);\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnancy;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy \\\u003C 24 months;\n12. Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study;\n13. Unwillingness to participate in this trial.","85 Years",{"count":62,"type":21},140,[64],"NA","Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein. Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.",[28],[68,69,70,71],"Deep venous thrombosis","Percutaneous mechanical thrombectomy","Post-thrombotic syndrome","Profunda femoris vein","NOT_YET_RECRUITING","2026-05-26",{"date":75,"type":44},"2026-06-03",{"date":77,"type":21},"2026-07-01",{"date":79,"type":21},"2029-07-30",{"name":81,"class":82},"RenJi Hospital","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":91,"targetDuration":93,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":83},"100637538","comparison-of-different-mechanical-thrombectomy-devices-in-endovascular-treatment-of-acute-iliofemoral-venous-thrombosis-100637538","NCT07622212","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)","Inclusion Criteria:\n\n1. Aged between 18 and 85 years;\n2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;\n5. Patients sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc.\n4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.\n5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or platelet count \\\u003C 80,000\u002FmL;\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnant women;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \\\u003C 24 months\n12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;\n13. Patients unwilling to participate in this trial.",{"count":92,"type":21},180,"24 Months","OBSERVATIONAL","A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.",[28],[68,69,70],{"date":75,"type":44},{"date":100,"type":44},"2024-01-01",{"date":102,"type":21},"2028-12-31",{"name":81,"class":82},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":94,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100507008","post-market-celect-platinum-vena-cava-filter-and-gunther-tulip-retrieval-set-study-100507008","NCT05881798","Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study","Post-Market Celect Platinum Vena Cava Filter and Günther Tulip Retrieval Set Study","Inclusion Criteria:\n\n* A patient dataset is deemed suitable for inclusion if the patient has a procedure where a Celect Platinum Vena Cava Filter is placed\n* Subject has not previously participated in the Cook MDR-2126 study.\n\nExclusion Criteria:\n\n* Patients will be excluded from enrollment if the patient or his\u002Fher legally authorized representative objects to collection and processing of his\u002Fher data or is not willing to sign the Informed Consent.",{"count":112,"type":21},82,"5 Years","This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.",[28,27,29],[117,118],"Celect Platinum Vena Cava Filter","Gunther Tulip Vena Cava Filter Retrieval Set","2026-04-14",{"date":121,"type":44},"2026-04-17",{"date":123,"type":44},"2025-06-02",{"date":125,"type":21},"2030-12",{"name":127,"class":128},"Cook Research Incorporated","INDUSTRY",7,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":83},"100584221","early-phase-1-apixaban-in-thrombocytopenia-100584221","NCT06886516","Apixaban in Thrombocytopenia","ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology","Inclusion Criteria:\n\n* Active malignancy defined as histologically confirmed diagnosis within last 6 months or received any cancer directed therapy within the last 6 months.\n* Radiologically confirmed newly diagnosed symptomatic deep vein thrombosis or pulmonary embolism within 28 days of enrollment. Includes proximal lower-limb DVT or symptomatic PE. Upper extremity or catheter-associated thrombosis will be included, as will distal lower extremity DVTs.\n* Platelet count \\\u003C 75,000\u002Fml (prior to platelet transfusion) within 28 days of VTE diagnosis.\n* Platelet count responsive to transfusion if previously administered (defined as an average platelet increase of at least 10,000\u002Fml over the last 3 transfusions.\n* No evidence of active hemorrhage.\n* No recent history of major hemorrhage (requiring transfusion, hospitalization or intervention) within the last 12 months.\n* No known brain metastases.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of apixaban in participants \\\u003C18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\n* ECOG performance status ≤2\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n  * Glomerular filtration rate (GFR) ≥25 mL\u002Fmin\u002F1.73\u002Fm2\n* Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* The effects of apixaban on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of apixaban administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who are receiving any other investigational agents.\n* Participants who have had a thrombectomy, insertion of a caval filter, or require a fibrinolytic agent.\n* Participants that have index events with severe clot burden defined as bilateral proximal lower extremity deep vein thrombosis and saddle embolism or pulmonary embolism with hemodynamic compromise.\n* Participants with acute myeloid leukemia or myelodysplastic syndrome or who are undergoing or have undergone allogeneic stem cell transplant.\n* Participants with luminal gastrointestinal malignancy or genitourinary cancer.\n* Presence of known or prior brain metastasis, given the increased risk of life-threatening intracranial hemorrhage with anticoagulant use. While screening for brain metastases is not standard of care in this population, investigators may obtain brain imaging if clinically indicated prior to initiation of anticoagulation. Imaging is not mandated in order to participate in this study.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to apixaban.\n* Participants receiving any medications or substances that are inhibitors or inducers of CYP3A\u002FP-gp are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Participants on aspirin (\\>100 mg\u002Fday), dual antiplatelet therapy, or receiving chronic treatment with NSAIDS\n* Participants with uncontrolled intercurrent illness.\n* Participants at high risk of bleeding such as:\n\n  * Unresected luminal\u002Fmucosal GI and GU cancers\n  * Active gastric or duodenal cancer\n  * History of major bleeding (based on ISTH criteria) in the past 12 months\n  * Any prior history of Intracranial hemorrhage (microhemorrhage is not included)\n  * Clinical or laboratory concern for ongoing DIC (prolonged PT\u002FAPTT or low fibrinogen)\n* Severe renal disease (CKD Stage IV or higher) or liver disease (Child Pugh B\u002FC)\n* Participants with pre-planned major surgery within the study period\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because apixaban has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with apixaban, breastfeeding should be discontinued if the mother is treated with apixaban.\n* Participant must be able to swallow pills.",{"count":138,"type":21},30,[140],"EARLY_PHASE1","This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes.\n\nThe name of the study drug involved in this study is:\n\n-Apixiban (a type of anticoagulant)",[28,143,144,145],"Pulmonary Embolism and Thrombosis","Thrombocytopenia","Recurrent Venous Thromboembolism",[27,28,29,144,147,145],"Thromboembolism","2026-04-10",{"date":150,"type":44},"2026-04-15",{"date":152,"type":44},"2025-02-28",{"date":154,"type":21},"2029-07-01",{"name":156,"class":82},"Rushad Patell",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":83},"100574015","timing-of-venous-thromboembolism-prophylaxis-in-patients-with-hypertensive-intracerebral-hemorrhage-100574015","NCT06753786","Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","Early or Delayed Initiation of Venous Thromboembolism Prophylaxis With Heparin in Patients With Hypertensive Intracerebral Hemorrhage","Inclusion Criteria:\n\n* the presence of hypertensive intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)\n* Being on an anticoagulant during preadmission period and on day of hospital admission\n* Death within the first 2 days after hospital admission\n* Detection of venous thromboembolism in a patient at the moment of hospital admission\n* Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin\n* The presence of a malignancy (cancer) in a patient at the moment of hospital admission",{"count":165,"type":21},200,[64],"The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral hemorrhage. The main questions it aims to answer are:\n\n* What is the optimal time for the beginning of anticoagulation with heparin to efficiently prevent venous thromboembolism in patients with hypertensive intracerebral hemorrhage? Early beginning (within the first 2 days but not earlier than 12 hours after the admission of a patient) or delayed beginning (on the third day after the admission of a patient)?\n* Which of the two timeframes (early or delayed) for anticoagulation beginning is the most safe in terms of bleeding complications including intracerebral hemorrhage expansion?\n\nResearchers will compare the results of early and delayed start of anticoagulation using heparin in patients with hypertensive intracerebral hemorrhage to define the optimal start time for anticoagulation that provides the most favourable efficiency\u002Fsafety profile.\n\nParticipants will:\n\n* Undergo a computed tomography (CT) scan of the brain on hospital admission and then 12-24 hours after the hospital admission and 24 hours after the beginning of venous thromboembolism prophylaxis using heparin;\n* Undergo the ultrasound examination of lower extremity deep veins on hospital admission and then once every 7 days;\n* Receive prophylactic doses of low molecular weight heparin or unfractionated heparin either beginning within the first 2 days but not earlier than 12 hours after the hospital admission or starting on the 3rd day after the hospital admission.",[27,29,169,28],"Intracerebral Hemorrhage",[171,172,173,174,175,176,177,178],"Prophylaxis","Deep vein thrombosis","Pulmonary embolism","Venous thromboembolism","Intracerebral hemorrhage","Anticoagulation","Low molecular weight heparin","Unfractionated heparin","2026-03-22",{"date":181,"type":44},"2026-03-24",{"date":183,"type":44},"2024-10-21",{"date":102,"type":21},{"name":186,"class":82},"Pirogov Russian National Research Medical University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":194,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":83},"100525671","comparison-of-percutaneous-mechanical-thrombectomy-with-different-access-in-treatment-of-acute-deep-venous-thrombosis-100525671","NCT06124768","Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis","Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis (The CODA Study)","Inclusion Criteria:\n\n1. Age between 18-85 years old;\n2. Acute DVT occurred no more than 14 days since the onset of disease;\n3. DVT treated by percutaneous mechanical thrombectomy\n4. Informed consent signed by patients.\n\nExclusion Criteria:\n\n1. Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;\n2. Women during pregnancy and lactation;\n3. Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\\\u003C6 months);\n4. Patients who are unable or unwilling to participate in the study.",{"count":195,"type":21},210,"The study aims to compare the modified approach through ipsilateral deep calf venous access or contralateral femoral venous access with the traditional approach through ipsilateral popliteal venous access for iliofemoral deep venous thrombosis (DVT) with distal popliteal vein thrombosis, and determine whether it can achieve similar therapeutic effects as iliofemoral DVT without distal popliteal vein thrombosis.",[28],[68,69,70],"2026-02-23",{"date":201,"type":44},"2026-02-25",{"date":203,"type":44},"2021-01-01",{"date":205,"type":21},"2027-10-31",{"name":81,"class":82},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":83},"100556003","non-invasive-venous-air-plethysmography-assessment-of-venous-hemodynamics-in-patients-suspected-deep-venous-obstruction-used-in-conjunction-with-intermittent-pneumatic-compression-100556003","NCT06519435","Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.","Inclusion Criteria:\n\n* Venous ultrasound study to evaluate for lower extremity DVT unilateral and\u002For bilateral within previous 72 hours.\n\nExclusion Criteria:\n\n* Patients with inaccessible target limb (ultrasound limb) due to bandages (wound, burn, lesion, etc) or cast.\n* Patients with leg trauma, fracture, above or below knee amputation, or other condition in which compressing on the calf is medically inappropriate or not possible.\n* Patients unable to provide informed written consent.",{"count":214,"type":21},500,"The purpose of this research is to measure changes in venous blood flow with an air-filled bladder under an intermittent pneumatic compression device cuff (used to prevent deep venous thrombosis) or venous diagnostic device cuff (used to detect deep venous thrombosis). The devices being used in the study are investigational and not FDA-cleared.",[28],"2025-10-25",{"date":219,"type":44},"2025-10-28",{"date":221,"type":44},"2024-11-15",{"date":223,"type":21},"2027-04",{"name":225,"class":82},"Mayo Clinic",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":241,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":83},"100415792","anticoagulant-plus-antiplatelet-therapy-following-iliac-vein-stenting-100415792","NCT04694248","Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting","Inclusion Criteria:\n\nIC1. Subjects who were diagnosed with deep venous thrombus (DVT) with ipsilateral iliac venous stenosis (\\>50%). The ipsilateral iliac venous stenosis can be caused either by iliac vein compression (i.e. Cockett syndrome) or residue iliac venous thrombus after percutaneous mechanic thrombectomy.\n\nIC2. Subjects who accepted percutaneous mechanic thrombectomy (PMT) to decrease the burden of thrombus, with or without catheter directed thrombolysis (CDT).\n\nIC3. Subjects who accepted iliac venous stent(s) implantation during the perioperative period of PMT or CDT (≤30 days post PMT or CDT) .\n\nExclusion Criteria:\n\nEC1. Subject has chronic DVT or the onset of DVT is longer than 3 weeks, or chronic DVT.\n\nEC2. Subject has isolated distal DVT, which does not affect ipsilateral femoral or iliac vein.\n\nEC3. Subject has glomerular filtration rate \\\u003C 60ml\u002Fmin. EC4. Subject has ipsilateral varicose vein or suffers from ipsilateral venous insufficiency prior to the DVT. The manifestations of venous insufficiency include skin pigmentation, edema, lipodermatosclerosis and venous ulcer.\n\nEC5. Subject has acute arterial embolism on either side or suffers from known moderate or greater stenosis at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery.\n\nEC6. Subject has known aneurysm(s) or current limiting dissection at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery.\n\nEC7. Subject has contraindication to antiplatelet drugs or anticoagulants. EC8. Subject has systemic disease(s) that cannot be treated by current medicine.\n\nEC9. Subject has been taking anticoagulants or antiplatelet drugs for other diseases prior to the DVT.\n\nEC10. Subject less than 18 years old or rejected to join this study. EC11. Subject has myocardial infarction during the past 6 months. EC12. EC12. Subject who is at high bleeding risk\\*.\n\n\\* Subject who has at least one of the below conditions will be considered at high bleeding risk: Primary history of intracerebral haemorrhage or ischemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR \\\u003C15ml\u002Fmin\u002F1.73 m2.",{"count":233,"type":21},172,[64],"To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.",[28,237,238,239,240],"Iliac Vein Thrombosis","Iliac Vein Obstruction","Iliac Vein Stenosis","Iliac Vein Compression Syndrome",[242,243],"acute proximal deep vein thrombosis","iliac vein stenting","2025-09-22",{"date":246,"type":44},"2025-09-25",{"date":248,"type":44},"2021-11-03",{"date":250,"type":21},"2027-06-30",{"name":252,"class":82},"First Affiliated Hospital of Zhejiang University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":83},"100447920","diagnosing-deep-vein-thrombosis-early-in-critically-ill-patients-100447920","NCT05112705","Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients","Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients (DETECT) Trial","DETECT","Inclusion criteria\n\n1. Medical, surgical or trauma ICU patients ≥18 years old.\n2. Patients who are expected to stay in the ICU more than 2 calendar days (unlikely to be discharged out of ICU on the day of admission or on the next day).\n\nExclusion Criteria\n\n1. Patients with DVT or PE diagnosed within the last year.\n2. Patients receiving chronic systemic anticoagulation.\n3. Patients who have received up to the time of ICU admission or are receiving therapeutic doses of anticoagulation with UFH, LMWH, or other anticoagulants.\n4. Inability or contraindication to obtain adequate ultrasound on the lower extremities (Burns in the lower extremities, lacerations, active skin infection, \\& ischemic limb in the legs, large dressings in the thighs that prevent adequate ultrasounds OR amputated foot or leg on one or two sides)\n5. Patients with Inferior Vena Cava (IVC) Filter.\n6. Known or suspected pregnancy.\n7. Limitation of life support, life expectancy \\\u003C7 days or palliative care.\n8. Previously enrolled in DETECT trial within the last 180 days.\n9. Enrolled in another trial for which co-enrolment is not approved.",{"count":262,"type":21},1800,[64],"The DETECT randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating DVT detection reduces the incidence of PE and lowers all-cause 90-day mortality. The primary outcome is 90-day all-cause mortality.",[28,29],"2025-09-15",{"date":268,"type":44},"2025-09-19",{"date":270,"type":44},"2023-03-21",{"date":272,"type":21},"2026-12",{"name":274,"class":82},"King Abdullah International Medical Research Center",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100560808","phase-4-individual-targeted-thrombosis-prophylaxis-versus-the-standard-one-size-fits-all-approach-in-patients-undergoing-total-hip-or-total-knee-replacement-100560808","NCT06581965","inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","The DISTINCT Trial: inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT: a National, Multicenter, Randomized, Multi-arm, Open-label Trial.","DISTINCT","Inclusion Criteria:\n\n* Scheduled to undergo an elective total hip arthroplasty or total knee arthroplasty\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Primary arthroplasty for fractures\n* Revision surgery\n* Hemiarthroplasty\n* Pregnancy\n* Current use of therapeutic anticoagulant therapy of any type (e.g., LMWH, DOAC, vitamin K antagonist)\n* A contraindication for either study drug\n* Insufficient knowledge of the Dutch language\n* Insufficient mental or physical ability to fulfil trial requirements\n* Active malignancy (i.e. cancer diagnosis within six months before surgery (excluding basal-cell or squamous-cell carcinoma of the skin), recently recurrent or progressive cancer or any cancer that required anti-cancer treatment within six months before surgery)\n* Patients using thrombocyte aggregation inhibitors that cannot be temporarily discontinued at the discretion of their treating physician",{"count":284,"type":21},10078,[286],"PHASE4","After hip or knee replacement all patients receive a standardized treatment with blood thinners, this medication is called thrombosis prophylaxis. However, despite this standard treatment some individuals still develop venous thrombosis (VTE), while others experience bleeding. This indicates that not all patients have the same VTE risk following surgery. Individualizing the amount of thrombosis prophylaxis following surgery might lead to less thrombotic and bleeding events. In this study the investigators individualize the treatment with thrombosis prophylaxis based on the medical history of a patient.\n\nThe main questions this study aims to answer are:\n\nCan thrombosis prophylaxis be shortened in patients with a low VTE risk to decrease the risk of bleeding without increasing the risk of VTE? Does an increase in the dose and duration of thrombosis prophylaxis in patients with a high VTE risk reduce the risk of VTE without inducing an unacceptable risk of bleeds?\n\nResearchers will compare both the shortened treatment in low VTE risk patients and the intensified and extended treatment in high VTE risk patients with the standard treatment to assess the risk of VTE and bleeding in comparison to the standard treatment.\n\nParticipants will receive 4 questionnaires to evaluate whether they have experienced a VTE or bleed. For this study no additional hospital visits are necessary.",[27,289,29,28],"Venous Thromboses",[174,171,291,292,293,294],"Individualized Medicine","Total hip arthroplasty","Total knee arthroplasty","Randomized controlled trial","2025-08-26",{"date":297,"type":44},"2025-09-03",{"date":299,"type":44},"2024-11-11",{"date":301,"type":21},"2031-02-01",{"name":303,"class":82},"Leiden University Medical Center",10,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":83},"100432916","compression-ultrasonography-in-non-high-probability-of-deep-vein-thrombosis-100432916","NCT04917328","Compression Ultrasonography in Non-high Probability of Deep Vein Thrombosis","Evaluation of the Predictive Value of Compression Venous Ultrasound by the Emergency Physician for Excluding the Diagnosis of Proximal Deep Vein Thrombosis (DVT) in Patients With Non-high Clinical Pretest Probability","EPREVUP","Inclusion Criteria:\n\n* adult patient\n* Patient presenting to the emergency department with clinical suspicion of DVT (i.e. pain and\u002For lower extremity edema).\n* Patient with a non-high probability according to the modified Wells score, i.e. a score of 0 or 1\n* Subject with a social health insurance plan\n* Subject able to understand the objectives and risks of the research and to give a signed and dated informed consent\n\nExclusion Criteria:\n\n* Patient with suspected pulmonary embolism\n* Patient with a high probability of DVT\n* Impossible to perform a whole leg doppler ultrasound within 5 days\n* Pregnant or breast-feeding woman, on patient's declaration\n* Subject under court protection\n* Subject under guardianship or curatorship",{"count":314,"type":21},700,[64],"Compression ultrasound is commonly used in emergency department. Accuracy to rule out deep vein thrombosis is excellent but lower then Ddimer assessment which is actually gold standard. With progress in formation of emergency physicians (EP), quality of material used, the investigators hypothesize that compression ultrasound can rule out deep vein thrombosis in case of non high probability, as standard care and DDimer assay.",[28],"2025-08-01",{"date":320,"type":44},"2025-08-03",{"date":322,"type":44},"2022-02-21",{"date":324,"type":21},"2027-02-28",{"name":326,"class":82},"University Hospital, Strasbourg, France",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":83},"100550740","intervention-to-improve-utilization-of-extended-venous-thromboembolism-prophylaxis-after-cancer-surgery-100550740","NCT06451003","Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery","An Equity Focused Intervention to Improve Utilization of Guideline Concordant Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery","SURGEON CLUSTER\n\nInclusion Criteria:\n\n* Surgeons performing cancer surgery within the Medical University of South Carolina (MUSC) system will be identified. Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion\u002Fexclusion criteria as follows. \"Abdominopelvic cancer surgery\" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy \u002F oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code.\n\nExclusion Criteria:\n\n* We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as ePpx duration is for 30 days postoperative.\n\nPATIENT SURVEY\n\nInclusion Criteria:\n\n* Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion\u002Fexclusion criteria as follows. \"Abdominopelvic cancer surgery\" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy \u002F oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code.\n\nExclusion Criteria:\n\n* We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as extended pharmacologic venous thromboembolism duration is for 30 days postoperative.\n* Lack of survey response.",{"count":138,"type":21},[64],"While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional medical societies. The reason why these medications are seldom prescribed is not well understood. The main questions this study aims to answer are:\n\n* Does surgeon education paired with an electronic medical record based decision support tool improve the guideline concordant prescription of pharmacologic venous thromboembolism after abdominopelvic cancer surgery?\n* Does dedicated patient education regarding blood clots at the time of hospital discharge after abdominopelvic cancer surgery improve understanding of the risk of venous thromboembolism and adherence to pharmacologic prophylaxis?\n\nThe investigators will study these questions using a stepped-wedge randomized trial where groups of surgeons will use a tool integrated to the electronic medical record to educate them on the individualized patient risks of blood clots after major cancer surgery and inform them regarding guidelines for preventative medicines. Utilization of the medications before and after using the tool will be compared.\n\nPatients will be administered a questionnaire assessing their awareness of blood clots as a risk after cancer surgery. For those prescribed medications to reduce blood clot risk after leaving the hospital, the questionnaire will evaluate whether they took the medications as prescribed. Survey results will be evaluated before and after implementation of education on blood clot risk at the time of hospital discharge.",[27,29,28,338,339],"Cancer","Surgery",[341,342,343,344,345,346],"venous thromboembolism","pulmonary embolism","deep vein thrombosis","cancer","surgery","clinical decision support system","2025-07-28",{"date":349,"type":44},"2025-07-31",{"date":351,"type":44},"2024-07-01",{"date":353,"type":21},"2026-12-31",{"name":355,"class":82},"Medical University of South Carolina",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":366,"studyType":94,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":378},"100553046","exclusion-of-venous-thrombo-embolism-with-a-new-clinical-decision-support-100553046","NCT06480994","Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support","Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support With Fresh Plasma, on Any Patient With VTE Suspicion","EXTEND","Inclusion Criteria:\n\n* PE and\u002For DVT suspicion\n* No opposition after informing the patient for his participation in research and processing of their data for this purpose,\n* Benefiting from the social security system\n\nExclusion Criteria:\n\n* Preventive or curative anticoagulant treatment, or fibrinolytic treatment,\n* Legal protection (e.g. guardianship or curatorship),\n* Pregnant or breastfeeding women.",{"count":365,"type":21},1836,"3 Months","The goal of this non interventional study is to demonstrate the diagnostic performances on fresh plasmas in comparison with the performances on frozen plasmas in any patients with VTE suspicion, whatever the pre-test probability. The main question it aims to answer is :\n\nAre the performances equivalent on fresh plasmas in comparison with frozen plasmas or is it necessary to determine a new algorithm of the Clinical Decision Support with a new cut-off? Participants will be diagnosed and treated in accordance with routine standard of care.",[27,29,28],"2025-06-23",{"date":371,"type":44},"2025-06-26",{"date":373,"type":44},"2022-06-21",{"date":375,"type":21},"2027-02",{"name":377,"class":128},"Diagnostica Stago R&D",4,{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100592117","a-multi-center-cohort-study-for-conventional-ultrasound-image-set-collection-to-create-a-data-set-for-research-purposes-100592117","NCT06989255","A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Data Set for Research Purposes.","A Multi-center Cohort Study for Conventional Ultrasound Image Set Collection to Create a Training Data Set for Research Purposes (Image Processing and Analysis, AI Model Training).","ThrombUS_A","Inclusion Criteria:\n\n* Age ≥18 years.\n* The participant has the capacity to consent, and consent is obtained prior to any study-specific procedures.\n* The conventional diagnostic DVT algorithm indicates that an ultrasound is needed, or the patient has been referred for a scan on suspicion of DVT.\n\nExclusion Criteria:\n\n* Patients with a known condition or reason that may potentially result in interrupting or stopping the ultrasound examination before its completion.\n* Patients considered by their treating physician or the ultrasound operator as non-suitable for a standard ultrasound scan.\n* Patients who have not signed the informed consent.",{"count":388,"type":21},3000,"This study aims to collect and create a labelled ultrasound image data set containing ultrasound image series and video clips of patients that undergo routine ultrasound scans on lower limbs, because of suspected deep vein thrombosis.\n\nThe data will be used to train an AI model within ThrombUS+ project to achieve automated detection of deep vein thrombosis on conventional ultrasound scans.\n\nPrimary objectives:\n\n1. Collect and curate imaging data from ultrasound scans of patients suspected for DVT.\n2. Collect accompanying metadata on patient demographics, referral note, existing known medical conditions at the time of scan, diagnosis based on the scan, operator anonymized ID, metadata on the ultrasound equipment used.\n3. Anonymize the data set according to established regulations to be used for research purposes and in specific for training an artificial intelligence model to achieve automated DVT detection.\n\nSecondary objectives:\n\n1\\. Describe the data set in the Argos\u002FOpenAIRE tool and make it publicly available through the European Open Science Cloud (EOSC) portal via OpenAIRE, to be used by other researchers for image processing, analysis, and artificial intelligence (AI) model training.",[28],[343,392,393,394],"ultrasound scan","lower limb","compression ultrasound","2025-05-16",{"date":397,"type":44},"2025-05-25",{"date":399,"type":44},"2024-11-06",{"date":401,"type":21},"2025-12-31",{"name":403,"class":82},"ThrombUS+",5,{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":83},"100461290","rheolytic-thrombectomy-for-acute-deep-vein-thrombosis-of-whole-lower-limb-100461290","NCT05286710","Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb","Clinical Study On The Improvement Of Rheolytic Thrombectomy For Acute Deep Vein Thrombosis Of Whole Lower Limb By Primary Popliteal Vein Thrombosis Clearance","Inclusion Criteria:\n\n* Age between 18-80 years old;\n* Acute DVT with clinical symptoms occurred less than 14 days since the onset of disease;\n* DVT with thrombosis involving the iliac vein, common femoral vein, distal popliteal vein, and\u002For calf vein;\n* Informed consent signed by patients.\n\nExclusion Criteria:\n\n* Patients with the previous history of the same side of lower-limb DVT;\n* Patients with plasma Creatinine level greater than 180umol\u002FL;\n* Patients who are contraindicated to thrombolysis;\n* Patients with inferior vena cava thrombosis;\n* Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;\n* Patients who have participated in a clinical trial in the past three months;\n* Women during pregnancy and lactation\n* Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\\\u003C2 years);\n* Patients with autoimmune thrombopathy or thrombocytopenia (platelets \\\u003C 80·10⁹\u002FL);\n* Patients who are unable or unwilling to participate in the study.","80 Years",{"count":414,"type":21},160,[64],"Ipsilateral popliteal venous the most common access for pharmacomechanical thrombectomy (PMT) in the treatment of acute deep venous thrombosis (DVT), but the result was not satisfactory. The investigators adjust the access to improve the thrombus clearance rate and reduce the incidence of post-thrombotic syndrome (PTS).",[28],[419],"pharmacomechanical thrombectomy","2025-05-13",{"date":422,"type":44},"2025-05-15",{"date":424,"type":44},"2022-09-01",{"date":426,"type":21},"2027-12-31",{"name":81,"class":82},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":438,"studyType":94,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":83},"100353396","ongoing-registry-of-treatment-of-venous-thromboembolism-100353396","NCT03881345","Ongoing Registry of Treatment of Venous Thromboembolism","Russian Registry of Treatment of Venous Thromboembolism","RRT VTE","Inclusion Criteria:\n\n* case of venous thrombosis of a limb or pulmonary embolus\n\nExclusion Criteria:\n\n* no exclusion criteria",{"count":437,"type":21},5000,"12 Months","Ongoing registration of patients with venous thromboembolism treated by means of antithrombotic therapy, thrombolisys, open surgery, endovenous desobstruction and stenting.",[28,441,442,443,29],"Thromboses, Venous","Thrombosis Embolism","Postthrombotic Syndrome","2025-05-05",{"date":446,"type":44},"2025-05-08",{"date":448,"type":44},"2019-04-01",{"date":450,"type":21},"2036-03-01",{"name":452,"class":82},"Medalp Private Surgery Clinic",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":466,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":479},"100475898","geko-venous-thromboembolism-prevention-study-100475898","NCT05476913","GEKO Venous Thromboembolism Prevention Study","A Randomised Controlled Trial of the Effectiveness of Intermittent Surface Neuromuscular Stimulation Using the Geko™ Device Compared With Intermittent Pneumatic Compression to Prevent Venous Thromboembolism in Immobile Acute Stroke Patients","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Clinical diagnosis of acute stroke (WHO criteria)\n3. Within 36 hours of symptom onset\n4. Not able to get up from a chair\u002Fout of bed and walk to the toilet without the help of another person\n\nExclusion Criteria:\n\n1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee\n2. Unwitnessed onset with a long lie on the floor before admission\n3. Clinically apparent deep vein thrombosis at screening\n4. Patient is expected to require palliative care within 14 days\n5. Patient does not live in the local catchment area and is expected to be transferred to their local hospital for on-going care.\n6. Patient has recently been involved in or is currently involved in a clinical trial for either a medical device or medicinal product, within the past 3 months, with the exception: if co-enrolment is not considered to impact adverse events or outcomes in the opinion of the Chief Investigator. (A live document containing a list of approved studies will be included in a reference document made available to all study sites and available upon request)\n7. Contraindications for the use of the geko™ device:\n\n   * Allergy to hydrogel constituents\n8. Contraindications to IPC:\n\n   * Severe peripheral vascular disease\n   * Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)\n   * Severe oedema\n   * Leg deformities making appropriate fitting impossible\n9. Uncontrolled congestive cardiac failure\n10. Pregnancy\n11. Single or double leg amputations",{"count":461,"type":21},1200,[64],"This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to receive either standard of care (Intermittent Pneumatic Compression) or geko™ neuromuscular electrostimulation device. The aim is to assess the prevention of VTE during a follow-up period of 90 days (three months) post-randomisation.",[465,27,28,29],"Stroke, Acute",[467,468,465,27,29,469],"geko","intermittent pneumatic compression","DVT prophylaxis","2025-02-27",{"date":472,"type":44},"2025-03-04",{"date":474,"type":44},"2023-07-06",{"date":476,"type":21},"2025-06-30",{"name":478,"class":128},"Firstkind Ltd",18,{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":22,"phases":490,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":83},"100580833","systematic-machine-learning-algorithm-for-rapid-thrombosis-detection-100580833","NCT06842446","Systematic Machine Learning Algorithm for Rapid Thrombosis Detection","Evaluating a New Diagnostic Strategy for Suspected DVT Consisting of Point of Care D-dimer, AI-based Prediction Model and Compression Ultrasound","DVT-SMART","Inclusion Criteria:\n\n* Patients referred to the ED due to suspicion of DVT\n* Age ≥ 18 years\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Ongoing use of anticoagulation for more than 72 hours\n* Previous participation in the study\n* Life expectancy of less than three months.",{"count":489,"type":21},1000,[64],"The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.",[28],[494,495,496],"Machine Learning","POC D-dimer","POC Ultrasound","2025-02-24",{"date":499,"type":44},"2025-02-26",{"date":501,"type":44},"2025-01-06",{"date":503,"type":21},"2029-01-05",{"name":505,"class":82},"Ostfold Hospital Trust",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":512,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":513,"targetDuration":113,"studyType":94,"phases":4,"briefSummary":514,"conditions":515,"keywords":530,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":404},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008","NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",true,{"count":388,"type":21},"This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[516,517,518,519,520,28,29,521,522,523,524,525,526,527,528,529],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Disseminated Intravascular Coagulation","Thrombophilia","Thrombotic Microangiopathies","Coagulation Factor Deficiency","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Platelet Dysfunction","Arterial Thromboembolism","Bleeding Disorder","Thrombosis",[529,531],"Hemostasis","2024-12-05",{"date":534,"type":44},"2024-12-11",{"date":536,"type":44},"2024-11-01",{"date":538,"type":21},"2030-12-31",{"name":540,"class":82},"Peking University People's Hospital",{"id":542,"slug":543,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":555,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":83},"100565950","microvisk-continuous-blood-donation-study-100565950","NCT06648837","Microvisk Continuous Blood Donation Study","Continuous Blood Donation for the Development of the Microvisk PT\u002FINR","Inclusion Criteria:\n\n* Currently undergoing Warfarin therapy.\n* Over 18 years old\n\nExclusion Criteria:\n\nA participant is not eligible for participation if ANY of the following criteria are met:\n\n* Participant is \\\u003C18 years of age\n* Participant is unable to give consent\n* Participant has been treated with Unfractionated Heparin, or Low Molecular Weight Heparin, within the last 7 days\n* Participant has, or is suspected of having, Anti-Phospholipid Syndrome (APS)\n* Participant is pregnant, or has been in the past 12 months\n* Participant is known to have HIV\u002FAIDS, is a carrier of Hepatitis A, B or C, has had tuberculosis or a tropical disease\n* Participant is suspected of intravenous drug use",{"count":549,"type":21},2500,[64],"Microvisk Technologies Ltd designs and develops test systems for monitoring the effectiveness of Warfarin and Warfarin-like medications.\n\nWarfarin and Warfarin-like medications are used to reduce the risk of stroke in people with an irregular heart rhythm (Atrial Fibrillation) or with mechanical heart valve replacements, as well as reducing the risk of recurrent Venous Thromboembolism.\n\nWarfarin dosing needs to be individualized. In order to correctly dose an individual in order to optimize the effectiveness of warfarin, and minimize the risk of bleeding, close monitoring of the degree of anticoagulation is required through regular blood testing. This test is known as PT\u002FINR (Prothrombin Time\u002FInternational Normalised Ratio). Simply, it is the measure of the amount of time (in seconds) it takes for your blood to clot.\n\nMicrovisk Technologies Ltd are developing new anticoagulant test strips for patients on warfarin or warfarin like medications. The blood collected as part of this study will be tested upon Microvisk's second generation Prothrombin\u002FInternational Normalized Ratio (PT\u002FINR) Test System. The donated blood will be used on ongoing development, validation, verification, and calibration projects. This study is being performed in partnership with the Oxford University Hospital (OUH) and Local Clinical Research Networks (LCRN) Thames Valley Core team, part of National Institute for Health and Care Research (NIHR).",[553,28,554],"Pulmonary Embolism (Diagnosis)","Atrial Fibrillation (AF)",[556,557,558,559,560,561],"PT","INR","PT\u002FINR","Warfarin","Vitamin K agonist","POC testing","2024-11-20",{"date":564,"type":44},"2024-11-21",{"date":566,"type":21},"2025-01-13",{"date":568,"type":21},"2029-11-01",{"name":570,"class":128},"Microvisk Technologies Ltd",{"id":572,"slug":573,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":579,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":83},"100533955","alerting-providers-at-patient-hospital-discharge-to-consider-prescribing-rivaroxaban-to-reduce-venous-thromboembolism-100533955","NCT06232551","Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","eVTE (Electronic Venous Thromboembolism): A Cluster, Randomized, Step-wedge Type II Hybrid Study of an Alert Recommending Extended Duration Thromboprophylaxis for At-risk Discharging Medical Patients to Prevent VTE.","eVTE","Inclusion Criteria:\n\n* Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:\n\n  * Physician, nurse practitioner, or physician assistant hospitalist\n  * Physician internal medicine\n  * Physician family medicine\n* Patient age ≥ 18 years.\n* The encounter must be inpatient.\n* A signed hospital discharge order must be present.\n* eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met\n\nExclusion Criteria:\n\n* Pregnant during encounter\n* Discharge order completed by ineligible clinician type\n* Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications):\n\n  * Apixaban\n  * Dabigatran\n  * Dalteparin\n  * Enoxaparin\n  * Edoxaban\n  * Betrixaban\n  * Fondaparinux\n  * Rivaroxaban\n  * Warfarin\n* Creatinine clearance \\\u003C30 milliliters\u002Fminute based on last-available eligible serum creatinine value preceding discharge\n\n  * Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \\* measured weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute\n  * If measured body weight not available, then based on ideal body weight ((140 - age years) \\* ideal body weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute","110 Years",{"count":581,"type":21},152000,[64],"A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.\n\nThe purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low.\n\nThe pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.",[585,143,28,586],"Venous Thromboembolic Disease","Hospitalism",[588,589,36,35,590],"post-discharge","extended duration thromboprophylaxis","medical patient","2024-07-15",{"date":593,"type":44},"2024-07-17",{"date":595,"type":44},"2024-06-01",{"date":597,"type":21},"2025-09-30",{"name":599,"class":82},"Scott C. Woller, MD",{"id":601,"slug":602,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":83},"100544180","tunneled-peripherally-inserted-central-catheter-picc-in-adult-patients-and-associated-outcomes-100544180","NCT06365528","Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes","Tunneled Versus Non-Tunneled Peripherally Inserted Central Catheter and Their Effects on Reducing Combined or Isolated Outcomes (Obstruction, Infection, Thrombosis, and Dislodgement): Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* adult patients (\\>= 18 years old) admitted to medical clinics, surgical clinics, or ICU, who have an indication for PICC insertion;\n\nExclusion Criteria:\n\n* patients with Chronic Kidney Disease, whether dialytic or not;\n* patients in critical or unstable condition characterized by the need for intubation, respiratory rate \\\u003C8 or \\>35 breaths per minute, oxygen saturation \\\u003C90%, heart rate \\\u003C40 or \\>140 beats per minute, systolic blood pressure \\\u003C90mmHg, decreased Glasgow Coma Scale \\>2 points, or prolonged (\\>5 minutes) or repeated seizures;\n* patients with cognitive deficits that impair their understanding of the study and do not have a responsible party to assist in this stage.",{"count":608,"type":21},840,[64],"The aim of this multicenter randomized clinical trial is to compare the tunneling technique of PICC insertion with the non-tunneled insertion technique in the incidence of the combined or isolated outcome of catheter-related bloodstream primary infection, thrombosis, obstruction, and accidental dislodgement in the adult population within a period of up to 30 days.",[612,28,613,614,615,616],"CLABSI - Central Line Associated Bloodstream Infection","Dislodged Catheter","Occlusion","Catheter Rupture","Catheter (Other); Complications","2024-05-16",{"date":619,"type":44},"2024-05-20",{"date":621,"type":44},"2024-05-06",{"date":623,"type":21},"2026-07-31",{"name":625,"class":82},"Hospital de Clinicas de Porto Alegre",{"id":627,"slug":628,"hasResults":11,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":633,"enrollmentInfo":634,"targetDuration":4,"studyType":22,"phases":636,"briefSummary":637,"conditions":638,"keywords":639,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":646,"leadSponsor":648,"locationsCount":4},"100437826","phase-3-the-api-calf-study-apixaban-to-treat-calf-vein-thrombosis-100437826","NCT04981327","The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis","API-CALF","Inclusion Criteria:\n\nConsecutive patients with acute (symptoms \\\u003C10 days) symptomatic iDDVT diagnosed on leg CUS who have none of the following exclusion criteria and who provided informed consent to participate. Diagnosis of iDDVT is made in the presence of an incompressible distal deep vein (deep calf vein (posterior tibial, anterior tibial or peroneal veins) or muscular vein (soleal or gastrocnemius veins)).\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Ipsi or contralateral Proximal DVT\n* Distal DVT involving the tibio-peroneal trunk (i.e. calf trifurcation)\n* DVT occurring while on anticoagulation (started ≥48hours before DVT diagnosis); However, inpatients that developed their iDDVT while on prophylactic anticoagulation are eligible if their expected date of discharge is \\\u003C6 days post randomization.\n* Clinically suspected PE (patient eligible if PE ruled out with objective tests)\n* Active cancer, receiving cancer treatment or cured for \\\u003C 6 months\n* Indication for long-term therapeutic anticoagulation (e.g. atrial fibrillation, mechanical heart valve…)\n* Thrombocytopenia (platelet count \\\u003C100 g\u002Fl)\n* Severe renal impairment (creatinine clearance \\\u003C30 ml\u002Fmin)\n* Liver disease (including Child-Pugh Class B and C) associated with coagulopathy\n* Pregnant or breast-feeding woman\n* Body weight \\>120kg or \\\u003C40 kg\n* Ongoing active bleeding or condition at high risk of bleeding with anticoagulation (e.g. peptic ulcer…)\n* Treatment with daily NSAIDs (aspirin ≤160 mg\u002Fday or clopidogrel ≤75 mg day permitted)\n* Allergy to Apixaban\n* Use of concomitant drugs that significantly interact with Apixaban: strong inhibitors of P-gp and CYP3A4 or strong inducers of CYP3A4\n* Treatment with anticoagulants at therapeutic dose \\>2 days after DVT diagnosis\n* Life expectancy \\\u003C 1 year\n* Enrolled in another clinical trial within previous 30 days\n* Inability or refusal to provide informed consent","120 Years",{"count":635,"type":21},1300,[24],"Isolated distal DVT (iDDVT) is the most frequent clinical presentation of VTE and is associated with a significant morbidity and risks of long-term complications. Data from clinical trials highlighted that patients with iDDVT might require some level of AC treatment. However, the optimal anticoagulant intensity is uncertain, and it is plausible that the best benefit\u002Frisk ratio for AC might be achieved with lower intensity doses rather than therapeutic doses.\n\nThe principal research question of the Apixaban to treat calf vein thrombosis (API-CALF) study is to determine whether, after a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID (experimental arm) is non inferior to Apixaban 5 mg BID (standard arm) in preventing VTE recurrence and bleeding in patients with iDDVT. Patients will be treated with Apixaban for a total of 3 months. In that perspective we will conduct an international multicentre open-label assessor-blinded study",[28],[640,176,641],"Isolated distal deep vein thrombosis","Direct oral anticoagulants","2021-07-22",{"date":644,"type":44},"2021-07-29",{"date":424,"type":21},{"date":647,"type":21},"2027-08-31",{"name":649,"class":82},"University Hospital, Geneva"]